YONDELIS® Mechanism of Action
How YONDELIS® Works
YONDELIS® is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix towards the major groove. Adduct formation triggers a cascade of events that can affect the subsequent activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell death.1
Efficacy
YONDELIS® is the only treatment approved specifically for unresectable or metastatic liposarcoma or leiomyosarcoma after an anthracycline-containing regimen1-3
Safety
Established in 6 open-label, single-arm trials, and 1 open-label, randomized, active-controlled clinical trial1
Ordering
Find information about ordering YONDELIS® from specialty distributors
Treatment Considerations
Considerations for treating unresectable or metastatic liposarcoma and leiomyosarcoma, 2 of the most common subtypes of soft tissue sarcoma4